Drug Delivery (Aug 2024)

Bone scaffolds-based localized drugs delivery for osteosarcoma: current status and future perspective

  • Wenqing Liang,
  • Hengguo Long,
  • Hongwei Zhang,
  • Juqin Bai,
  • Bo Jiang,
  • Jiangwei Wang,
  • Lifeng Fu,
  • Wenyi Ming,
  • Jiayi Zhao,
  • Bin Zeng

DOI
https://doi.org/10.1080/10717544.2024.2391001
Journal volume & issue
Vol. 31, no. 1

Abstract

Read online

A common malignant bone neoplasm in teenagers is Osteosarcoma. Chemotherapy, surgical therapy, and radiation therapy together comprise the usual clinical course of treatment for Osteosarcoma. While Osteosarcoma and other bone tumors are typically treated surgically, however, surgical resection frequently fails to completely eradicate tumors, and in turn becomes the primary reason for postoperative recurrence and metastasis, ultimately leading to a high rate of mortality. Patients still require radiation and/or chemotherapy after surgery to stop the spread of the tumor and its metastases, and both treatments have an adverse influence on the body’s organ systems. In the postoperative management of osteosarcoma, bone scaffolds can load cargos (growth factors or drugs) and function as drug delivery systems (DDSs). This review describes the different kinds of bone scaffolds that are currently available and highlights key studies that use scaffolds as DDSs for the treatment of osteosarcomas. The discussion also includes difficulties and perspectives regarding the use of scaffold-based DDSs. The study may serve as a source for outlining efficient and secure postoperative osteosarcoma treatment plans.

Keywords